SkyOak Wealth LLC Reduces Stake in Lantheus Holdings, Inc. $LNTH

SkyOak Wealth LLC reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 30.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,419 shares of the medical equipment provider’s stock after selling 19,865 shares during the period. SkyOak Wealth LLC owned about 0.07% of Lantheus worth $4,928,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in shares of Lantheus in the 2nd quarter worth approximately $575,628,000. Farallon Capital Management LLC increased its position in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after buying an additional 1,950,252 shares during the last quarter. Norges Bank purchased a new stake in Lantheus in the fourth quarter worth $76,197,000. Freestone Grove Partners LP raised its stake in shares of Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after buying an additional 594,088 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after buying an additional 582,661 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on LNTH shares. Mizuho cut their price target on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. B. Riley Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Weiss Ratings upgraded shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 27th. Finally, William Blair set a $102.50 target price on shares of Lantheus in a research note on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $108.11.

Lantheus Price Performance

Lantheus stock opened at $100.88 on Wednesday. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86. The business has a fifty day moving average price of $103.53 and a 200-day moving average price of $92.24. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The firm has a market capitalization of $6.58 billion, a P/E ratio of 24.37 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.57 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.